Earnings summaries and quarterly performance for Integer Holdings.
Executive leadership at Integer Holdings.
Payman Khales
Detailed
President and Chief Executive Officer
CEO
Diron Smith
Detailed
Executive Vice President and Chief Financial Officer
Jim Stephens
Detailed
President, Cardiac Rhythm Management & Neuromodulation
John Harris
Detailed
Executive Vice President, Global Operations and Manufacturing Strategy
Lindsay Blackwood
Detailed
Senior Vice President, General Counsel and Corporate Secretary
Board of directors at Integer Holdings.
Cheryl Capps
Detailed
Director
Craig Maxwell
Detailed
Director
Donald Spence
Detailed
Director
Filippo Passerini
Detailed
Director
James Hinrichs
Detailed
Director
Jean Hobby
Detailed
Director
Michael Coyle
Detailed
Director
Pamela Bailey
Detailed
Chair of the Board
Sheila Antrum
Detailed
Director
Tyrone Jeffers
Detailed
Director
Research analysts who have asked questions during Integer Holdings earnings calls.
Richard Newitter
Truist Securities
6 questions for ITGR
Also covers: AXNX, DXCM, GKOS +18 more
Suraj Kalia
Oppenheimer & Co. Inc.
6 questions for ITGR
Also covers: ABT, AORT, ATRC +14 more
Joanne Wuensch
Citigroup Inc.
5 questions for ITGR
Also covers: ABT, BAX, BDX +18 more
Nathan Treybeck
Wells Fargo Securities
5 questions for ITGR
Also covers: IRTC, LMAT, NVRO +1 more
Andrew Cooper
Raymond James
4 questions for ITGR
Also covers: AZTA, CDNA, CTKB +12 more
Brett Fishbin
KeyBanc Capital Markets
4 questions for ITGR
Also covers: ALC, COO, ICUI +6 more
Craig Bijou
Bank of America Securities
4 questions for ITGR
Also covers: BLCO, COO, FNA +9 more
Matthew O'Brien
Piper Sandler & Co.
3 questions for ITGR
Also covers: APYX, ATEC, ATRC +18 more
Brett Fishman
KeyBanc Capital Markets Inc.
2 questions for ITGR
Also covers: SOLV
Matthew O'Brien
Piper Sandler
2 questions for ITGR
Also covers: DXCM, KMTS
Travis Steed
Bank of America
2 questions for ITGR
Also covers: ABT, AXNX, BAX +19 more
Kristen Stewart
CL King & Associates
1 question for ITGR
Also covers: AVNS, CNMD, HAE +3 more
Matt O'Brien
Piper Sandler Companies
1 question for ITGR
Also covers: BBNX, BSX, DXCM +6 more
Recent press releases and 8-K filings for ITGR.
Integer Holdings Corporation Faces Securities Class Action
ITGR
Legal Proceedings
Guidance Update
Demand Weakening
- A class action lawsuit has been filed against Integer Holdings Corporation (ITGR) on behalf of investors who purchased securities between July 25, 2024, and October 22, 2025.
- The lawsuit alleges that Integer misled investors regarding the demand for its electrophysiology (EP) devices, which was actually decelerating, and vastly overstated its market position.
- On October 23, 2025, Integer cut its full-year 2025 guidance to -2% to 2% net sales growth and provided 2026 organic sales growth guidance of 0% to 4%, attributing this to slower than forecasted market adoption for two EP devices.
- Following this announcement, Integer's common stock fell $35.22 per share, or more than 32%, closing at $73.89 per share on October 23, 2025.
- The deadline for shareholders to submit papers to serve as lead plaintiff in the class action is February 9, 2026.
13 hours ago
Integer Holdings Corporation Subject to Securities Class Action
ITGR
Legal Proceedings
Guidance Update
Demand Weakening
- Robbins LLP has filed a class action lawsuit on behalf of investors who purchased Integer Holdings Corporation securities between July 25, 2024, and October 22, 2025.
- The lawsuit alleges that Integer Holdings Corporation misled investors regarding its market position and demand for its electrophysiology (EP) devices, claiming demand had significantly decreased.
- On October 23, 2025, Integer cut its full-year 2025 guidance and projected 0% to 4% organic sales growth for 2026, acknowledging slower than forecasted market adoption for two EP devices.
- Following this announcement, Integer's common stock fell $35.22 per share, or more than 32%, closing at $73.89 per share on October 23, 2025.
1 day ago
Integer Holdings Faces Class Action Lawsuit
ITGR
Legal Proceedings
Demand Weakening
- Rosen Law Firm has announced a class action lawsuit against Integer Holdings Corporation (NYSE: ITGR) on behalf of stockholders who purchased common stock during the Class Period from July 25, 2024, to October 22, 2025.
- The lawsuit alleges that Integer Holdings Corporation misled investors by materially overstating its competitive position in the electrophysiology (EP) manufacturing market and failing to disclose a sustained deterioration in sales for two of its EP devices.
- It is also claimed that Integer mischaracterized its EP devices as a long-term growth driver for its cardio and vascular (C&V) segment, leading to materially false and misleading statements about the company's business, operations, and prospects.
- Shareholders wishing to serve as lead plaintiff in the class action must file their motions with the court by February 9, 2026.
1 day ago
Integer Holdings Corporation Discusses CEO Transition, Share Repurchase, and 2026 Outlook
ITGR
CEO Change
Share Buyback
Guidance Update
- Integer Holdings Corporation recently underwent a CEO transition with Payman Khales taking the helm.
- The company's board authorized a $200 million share repurchase program, its first ever, as management believes the stock is undervalued following a Q3 reaction.
- For 2026, the core business is expected to grow 4%-7%, but this will be offset by short-term headwinds from three specific products (two electrophysiology, one neuro) due to lower-than-anticipated market adoption rates.
- Management anticipates these headwinds to primarily impact the first half of 2026, with a projected return to market growth in the second half of 2026 and above-market growth in 2027.
- The company's M&A strategy is focused on targeted, tuck-in acquisitions to build critical capabilities, rather than transformative deals.
Dec 3, 2025, 2:45 PM
Integer Holdings Corporation Discusses 2026 Headwinds and Share Repurchase Program
ITGR
Guidance Update
Share Buyback
Demand Weakening
- Integer Holdings Corporation (ITGR) projects its core business to grow 4%-7% in 2026, slightly above its weighted average market growth rate of 4%-6%.
- The company anticipates short-term headwinds in the first half of 2026 due to lower market adoption for three specific products (two electrophysiology and one neuro product), leading to an operating margin outlook for 2026 of down 5% to up 4%.
- The Board has authorized a $200 million share repurchase program, marking the company's first, as management believes the stock is undervalued.
- Management expects a return to market growth in the second half of 2026 and above-market growth (200 basis points) in 2027, primarily driven by new product launches.
Dec 3, 2025, 2:45 PM
Integer Discusses 2026 Headwinds, Share Repurchase, and Future Growth at Healthcare Conference
ITGR
Guidance Update
Share Buyback
CEO Change
- Integer's new CEO expressed bullishness on the business, highlighting its role as a leading contract development and manufacturing organization (CDMO) focused on high-growth medtech markets including electrophysiology, neurovascular, structural heart, and neuromodulation.
- The company expects short-term headwinds in 2026, primarily in the first half, attributed to lower-than-anticipated market adoption for three specific products (two electrophysiology and one neuro product). Despite this, the core business is projected to grow 4% to 7% , with a return to market growth in the second half of 2026 and above-market growth in 2027.
- The board authorized a $200 million share repurchase program, marking the first such initiative for the company, reflecting confidence in its fundamentals and a belief that the stock is undervalued.
- Integer's global manufacturing footprint is viewed as a competitive advantage, helping manage tariffs, which are estimated to have a limited impact of $1 million-$5 million in 2025.
Dec 3, 2025, 2:45 PM
Integer Holdings Corporation Updates 2026 Outlook and Announces Share Repurchase
ITGR
Guidance Update
Demand Weakening
Share Buyback
- Integer Holdings Corporation (ITGR) projects 2026 reported sales to be down 2% to up 2%, incorporating a 3-4% headwind from three specific new products and a 2% headwind from exiting its portable medical business.
- The company's core business organic growth for 2026 is expected to be flat to plus 4%, with headwinds being more pronounced in the first half of the year and abating in the second half due to easier 2025 comparables.
- CEO Payman Khales noted that the simultaneous underperformance of three products is highly unusual and temporary, and the company anticipates returning to above-market performance in 2027 driven by a strong development pipeline.
- The board authorized a $200 million share repurchase program, which will be funded by cash on hand and free cash flow, serving as an additional capital allocation lever.
- Operating margin guidance for 2026 is down 5% to up 4%, as lower sales volumes will pressure fixed cost leverage despite continued variable cost efficiencies.
Dec 2, 2025, 1:00 PM
Integer (ITGR) Provides 2026 Guidance Update and Capital Allocation Plans
ITGR
Guidance Update
Demand Weakening
Share Buyback
- Integer (ITGR) projects its 2026 core business to grow 4-7%, which is in line with or slightly above its weighted average market growth rate of 4-6%.
- However, the company's 2026 reported sales guidance is down 2% to up 2%, reflecting a 3-4% headwind from three underperforming new products and an additional 2% headwind from the strategic exit of its portable medical business.
- These headwinds are expected to be more pronounced in the first half of 2026, leading to a more significant reduction in Q1 2026 compared to Q4 2025, with a return to market growth anticipated in the second half of 2026 due to easier comparables.
- Integer expects to return to above-market performance in 2027, supported by a robust product pipeline, 80% of which is geared towards faster-growing markets.
- The board has authorized a $200 million share repurchase program, providing an additional lever for capital allocation alongside organic investment and tuck-in acquisitions.
Dec 2, 2025, 1:00 PM
Integer Holdings Corporation Provides 2026 Growth Outlook Amidst Product Headwinds
ITGR
Guidance Update
Demand Weakening
Share Buyback
- Integer Holdings Corporation (ITGR) projects 2026 reported growth to be down 2% to up 2%, primarily due to 3%-4% headwinds from three specific new products and a 2% headwind from the exit of its portable medical business.
- Despite these challenges, the company's core business is expected to grow 4%-7% in 2026, in line with or slightly above its weighted average market growth rate of 4%-6%.
- The impact of the headwinds is anticipated to be more significant in the first half of 2026, with a projected return to market growth in the second half of 2026 and above market performance in 2027, supported by a robust development pipeline.
- Integer's development sales, a leading indicator of its pipeline, are expected to have grown 3x from 2017 by the end of 2025, with 80% directed towards high-growth markets such as electrophysiology and neurovascular.
- For 2026, the company forecasts its operating margin to be down 5% to up 4% due to lower sales volumes impacting fixed cost leverage, and its board has authorized a $200 million share repurchase program.
Dec 2, 2025, 1:00 PM
Integer Holdings Board Authorizes $200 Million Share Repurchase Program
ITGR
Share Buyback
- Integer Holdings Corporation's Board of Directors has authorized a share repurchase program of up to $200 million of its outstanding common stock.
- The company intends to fund the program primarily using cash on hand and free cash flows.
- The timing and volume of share repurchases will be executed at the discretion of management.
Nov 4, 2025, 1:00 PM
Quarterly earnings call transcripts for Integer Holdings.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more